Technology Transfer Office

Fiscal Year 2006 Report
Dear Friends,

Fiscal year 2006 was one in which Case continued to reach new heights in the field of technology transfer. We continued to build upon the strong momentum that began in late fiscal year 2002 when the current Technology Transfer Office was established. Our commitment to the university and the community then, as it is now, was to create and sustain a world-class technology transfer function to move innovations created by Case’s world-class researchers into the marketplace to benefit society. With strong support from faculty, administrators, and the leadership of the institution, and with a dedicated team of professionals, we have built an organization that is now recognized as a national leader and that ranks among the best institutions in the country across a wide range of metrics.

The past year has seen us reach new levels of performance in areas such as invention disclosures received and transactions completed (which were up 36 and 42 percent, respectively, over the previous year). This is a powerful indication of our engagement with our researchers and with industry, and will translate into more technologies developed at Case and its affiliate institutions reaching the public, which remains our primary goal.

This report, in an electronic presentation format, details some of the highlights of our operation and results for the past year, as well as information on several of the newest companies that Case has financed via the Case Technology Ventures pre-seed stage investment fund. We hope you enjoy this report, and we look forward to continuing to work with you in the coming year.

Mark Coticchia
Vice President
Research and Technology Management

Nick Frollini
Assistant Vice President for Technology Transfer
Engineering & Physical Sciences and Operations

Joseph Jankowski, Ph.D.
Assistant Vice President for Technology Transfer
Biomedical Sciences
Invention disclosures, which are an important measure of faculty involvement in the technology transfer process, reached a new record level of 174 in FY 2006.
Tech Transfer continues to handle a large and increasing number of Material Transfer Agreements (MTAs) and Non-Disclosure Agreements (NDAs), which aid the university’s commercialization activities and enhance customer service for researchers across the institution.
Case’s goal is to create 3 to 4 new companies in each year, some of which may receive investment from our Case Technology Ventures fund.
Our transaction volume (license, option, and related agreements) continues to increase substantially year over year. This bodes well for the future of our operation, and means more technology developed by our researchers will reach the public.

<table>
<thead>
<tr>
<th>Year</th>
<th>Transactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2001</td>
<td>6</td>
</tr>
<tr>
<td>FY 2002</td>
<td>10</td>
</tr>
<tr>
<td>FY 2003</td>
<td>15</td>
</tr>
<tr>
<td>FY 2004</td>
<td>18</td>
</tr>
<tr>
<td>FY 2005</td>
<td>26</td>
</tr>
<tr>
<td>FY 2006</td>
<td>37</td>
</tr>
</tbody>
</table>
Our revenue shows solid, sustainable growth, indicating that we have built a strong infrastructure at Case for technology transfer.

Since the inception of the current program in late fiscal year 2002, approximately $21 million has been distributed to inventors at Case and its affiliate institutions; the balance of the university’s proceeds have been used to support programs across campus.
New Case Technology Ventures
Portfolio Companies

Case Technology Ventures (CTV), the university’s internal, pre-seed stage fund invested in two companies in the most recent fiscal year. CTV has several other transactions in the works and expects to make additional announcements during fiscal year 2007.

Great Lakes Pharmaceuticals is a clinical stage company focused on development and commercialization of products designed to prevent infections associated with indwelling catheters. The company was founded by industry veteran Krzysztof Appelt in conjunction with Case and Ricerca Biosciences. It is developing products based on technologies licensed from Case/University Hospitals of Cleveland and other leading research institutions.

Synapse Biomedical is a northeast Ohio based medical device company focused on the development and commercialization of minimally invasive neurostimulation technologies for the diagnosis and treatment of neurodegenerative disease. Synapse has licensed technologies developed by researchers at Case and University Hospitals of Cleveland.
Learn More About Technology Transfer

To learn more about the Technology Transfer Office at Case, including contact information for our team of licensing professionals, please visit our website at: http://techtransfer.case.edu.

Technology Transfer Office
Case Western Reserve University
10900 Euclid Avenue, Sears Building, 6th Floor
Cleveland, OH 44106-7219

Fax: 216-368-0196